Berenberg analysts say Sanofi's expanded Regeneron collaboration frees it to deploy €30B-€40B on M&A to refill its late-stage pipeline. Next key data: frexalimab in MS and brivekimig in HS, both due H2 2027. Shares up 1%.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
